We aimed to investigate whether in vitro fermentation of soy with L. plantarum could promote its beneficial effects on lipids at the molecular and physiological levels. Rats were fed an AIN76A diet containing 50% sucrose (w/w) (CTRL), a modified AIN76A diet supplemented with 1% (w/w) cholesterol (CHOL), or a CHOL diet where 20% casein was replaced with soy milk (SOY) or fermented soy milk (FSOY). Dietary isoflavone profiles, serum lipids, hepatic and fecal cholesterol, and tissue gene expression were examined. The FSOY diet had more aglycones than did the SOY diet. Both the SOY and FSOY groups had lower hepatic cholesterol and serum triglyceride (TG) than did the CHOL group. Only FSOY reduced hepatic TG and serum free fatty acids and increased serum HDL-CHOL and fecal cholesterol. Compared to CHOL, FSOY lowered levels of the nuclear forms of SREBP-1c and SREBP-2 and expression of their target genes, including FAS, SCD1, LDLR, and HMGCR. On the other hand, FSOY elevated adipose expression levels of genes involved in TG-rich lipoprotein uptake (ApoE, VLDLR, and Lrp1), fatty acid oxidation (PPARα, CPT1α, LCAD, CYP4A1, UCP2, and UCP3), HDL-biogenesis (ABCA1, ApoA1, and LXRα), and adiponectin signaling (AdipoQ, AdipoR1, and AdipoR2), as well as levels of phosphorylated AMPK and ACC. SOY conferred a similar expression profile in both liver and adipose tissues but failed to reach statistical significance in many of the genes tested, unlike FSOY. Our data indicate that fermentation may be a way to enhance the beneficial effects of soy on lipid metabolism, in part via promoting a reduction of SREBP-dependent cholesterol and TG synthesis in the liver, and enhancing adiponectin signaling and PPARα-induced expression of genes involved in TG-rich lipoprotein clearance, fatty acid oxidation, and reverse cholesterol transport in adipose tissues.
References
[1]
Khoo KL, Tan H, Liew YM, Deslypere JP, Janus E (2003) Lipids and coronary heart disease in Asia. Atherosclerosis 169: 1–10. doi: 10.1016/s0021-9150(03)00009-1
[2]
Grundy SM (1998) Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81: 18B–25B. doi: 10.1016/s0002-9149(98)00033-2
[3]
Spady DK, Woollett LA, Dietschy JM (1993) Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids. Annu Rev Nutr 13: 355–381. doi: 10.1146/annurev.nu.13.070193.002035
[4]
Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, et al. (2007) Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutrit 85: 1148–1156.
[5]
Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, et al. (2009) Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol 44: 471–477. doi: 10.1080/00365520802588133
[6]
Lin Y, Meijer GW, Vermeer MA, Trautwein EA (2004) Soy protein enhances the cholesterol-lowering effect of plant sterol esters in cholesterol-fed hamsters. The Journal of nutrition 134: 143–148.
[7]
Hoie LH, Morgenstern EC, Gruenwald J, Graubaum HJ, Busch R, et al. (2005) A double-blind placebo-controlled clinical trial compares the cholesterol-lowering effects of two different soy protein preparations in hypercholesterolemic subjects. European journal of nutrition 44: 65–71. doi: 10.1007/s00394-004-0492-0
[8]
Anthony MS, Clarkson TB, Hughes CL Jr, Morgan TM, Burke GL (1996) Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr 126: 43–50.
[9]
Fukui K, Tachibana N, Wanezaki S, Tsuzaki S, Takamatsu K, et al. (2002) Isoflavone-free soy protein prepared by column chromatography reduces plasma cholesterol in rats. Journal of agricultural and food chemistry 50: 5717–5721. doi: 10.1021/jf025642f
[10]
Chien HL, Huang HY, Chou CC (2006) Transformation of isoflavone phytoestrogens during the fermentation of soymilk with lactic acid bacteria and bifidobacteria. Food Microbiol 23: 772–778. doi: 10.1016/j.fm.2006.01.002
[11]
Izumi T, Piskula MK, Osawa S, Obata A, Tobe K, et al. (2000) Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 130: 1695–1699.
[12]
Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125–1131. doi: 10.1172/jci0215593
[13]
Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, et al. (2002) Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 277: 11019–11025. doi: 10.1074/jbc.m111041200
[14]
Field FJ, Born E, Murthy S, Mathur SN (2001) Regulation of sterol regulatory element-binding proteins by cholesterol flux in CaCo-2 cells. J Lipid Res 42: 1687–1698.
[15]
Chambers CM, Ness GC (1997) Translational regulation of hepatic HMG-CoA reductase by dietary cholesterol. Biochem Biophys Res Commun 232: 278–281. doi: 10.1006/bbrc.1997.6288
[16]
Ascencio C, Torres N, Isoard-Acosta F, Gomez-Perez FJ, Hernandez-Pando R, et al. (2004) Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 134: 522–529.
[17]
Kano M, Takayanagi T, Harada K, Sawada S, Ishikawa F (2006) Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J Nutr 136: 2291–2296.
[18]
Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 224: 497–509.
[19]
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.
[20]
Haglund O, Luostarinen R, Wallin R, Wibell L, Saldeen T (1991) The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr. 121: 165–169.
[21]
de Wael J, Raaymakers CE, Endeman HJ (1977) Simplified quantitative determination of total fecal bile acids. Clin Chim Acta 79: 465–470. doi: 10.1016/0009-8981(77)90443-0
[22]
Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, et al. (2012) AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res 53: 2490–2514. doi: 10.1194/jlr.r025882
[23]
Di Cagno R, Mazzacane F, Rizzello CG, Vincentini O, Silano M, et al. (2010) Synthesis of isoflavone aglycones and equol in soy milks fermented by food-related lactic acid bacteria and their effect on human intestinal Caco-2 cells. J Agric Food Chem 58: 10338–10346. doi: 10.1021/jf101513r
[24]
Torre-Villalvazo I, Tovar AR, Ramos-Barragan VE, Cerbon-Cervantes MA, Torres N (2008) Soy protein ameliorates metabolic abnormalities in liver and adipose tissue of rats fed a high fat diet. J Nutr 138: 462–468.
[25]
Carling D, Clarke PR, Zammit VA, Hardie DG (1989) Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem 186: 129–136. doi: 10.1111/j.1432-1033.1989.tb15186.x
[26]
Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, et al. (1999) The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104: R25–31. doi: 10.1172/jci8119
[27]
Schwartz K, Lawn RM, Wade DP (2000) ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun 274: 794–802. doi: 10.1006/bbrc.2000.3243
[28]
Tacken PJ, Teusink B, Jong MC, Harats D, Havekes LM, et al. (2000) LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J Lipid Res 41: 2055–2062. doi: 10.1016/s0021-9150(00)81351-9
[29]
Espirito Santo SM, Rensen PC, Goudriaan JR, Bensadoun A, Bovenschen N, et al. (2005) Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J Lipid Res 46: 1097–1102. doi: 10.1194/jlr.c500007-jlr200
[30]
Rakhshandehroo M, Knoch B, Muller M, Kersten S (2010) Peroxisome proliferator-activated receptor alpha target genes. PPAR Res 2010.
[31]
Rossmeisl M, Kovar J, Syrovy I, Flachs P, Bobkova D, et al. (2005) Triglyceride-lowering effect of respiratory uncoupling in white adipose tissue. Obes Res 13: 835–844. doi: 10.1038/oby.2005.96
[32]
Kadowaki T, Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26: 439–451. doi: 10.1210/er.2005-0005
[33]
Lewis GF (1997) Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8: 146–153. doi: 10.1097/00041433-199706000-00004
